Population Pharmacokinetic Analysis of Tesamorelin in HIV-Infected Patients and Healthy Subjects

Clinical Pharmacokinetics

Volumn 54, Issue 3, 2015, Pages 285-294

  González Sales, Mario ^a,b   Barrière, Olivier ^b   Tremblay, Pierre Olivier ^b   Nekka, Fahima ^a   Mamputu, Jean Claude ^c   Boudreault, Sylvie ^b   Tanguay, Mario ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SYNEOS HEALTH   (United States)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TESAMORELIN; GROWTH HORMONE RELEASING FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; OPEN STUDY; PHARMACOKINETIC ASSAY; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; BLOOD; BODY MASS; CLINICAL TRIAL; HIV INFECTIONS; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

BODY MASS INDEX; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 84923771571     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0202-x     Document Type: Article

References (15)

1. Wierzbicki AS, Purdon SD, Hardman TC, et al. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res Opin. 2008;24:609–24.
2. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563–608.
3. Stanley TL, Grinspoon SK. Body composition and metabolic changes in HIV-infected patients. J Infect Dis. 2012;205:S383–90.
4. Falutz J. Management of fat accumulation in patients with HIV infection. Curr HIV/AIDS Rep. 2011;8:200–8.
5. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab. 2001;86:504–10.
6. Benedini S, Terruzzi I, Lazzarin A, et al. Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy. BioDrugs. 2008;22:101–12.
7. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96:150–8.
8. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95:4291–304.
9. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54:1642–51.
10. Savic RM, Karlsson MO. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17–20.
11. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic–pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511–28.
12. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28:171–92.
13. Brendel K, Comets E, Laffont C, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036–49.
14. Efron B, Tibshirani R. An introduction to the bootstrap. Chapman & Hall;1993.
15. Michaud S-É, Abolfathi Z, Potvin D, et al. Pharmacokinetic/pharmacodynamic evaluation of tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analog, administered subcutaneously once daily for 14 consecutive days in healthy and hiv positive populations [abstract no. 230073]. Endocrine Society’s Annual Meeting: Washington DC;2009.